Nexalin Technology Secures U.S. Patent for Dynamic Frequency Stimulation, Strengthening IP Through 2042
NXL sits 83% above its 52-week low of $0.305 on light trading volume (0.3× avg).
Summary
Nexalin Technology announced the issuance of a U.S. patent covering its dynamic frequency stimulation method for anxiety, depression, and insomnia. This patent provides intellectual property protection through 2042, strengthening the company's competitive position. The news is a positive development for the company, which has recently faced going concern warnings and Nasdaq delisting threats, as strong IP is crucial for its long-term strategy and commercialization efforts for its HALO™ Clarity and NeuroCare™ platforms.
At the time of this announcement, NXL was trading at $0.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5M. The 52-week trading range was $0.31 to $2.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.